Clinical Trial Update: Effect of Recombinant Erythropoietin on Numbers of Circulating Endothelial Progenitor Cells in Subacute TBI [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating recombinant erythropoietin on circulating endothelial progenitor cells in subacute traumatic brain injury has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Traumatic Brain Injury

Drugs mentioned

• Recombinant erythropoietin (erythropoietin)

Snippet

Sponsor: Uniformed Services University of the Health Sciences | Conditions: Traumatic Brain Injury | Phase 2 | Status: WITHDRAWN